Immuron Commences US Non-Deal Institutional Investor Roadshow MELBOURNE, Australia, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is pleased to release to shareholders and investors...

Immuron Approved to Commence Clinical Study in C.Difficile Infection (CDI) Key Highlights Final approval for key first in-human Clinical Study for CDI treatment, by Israeli Ministry of HealthAn estimated 28,000 patients die each year from CDI infections in the USA...

HiberGene Launches HG C. Difficile Test DUBLIN, Ireland, Dec. 15, 2016 (GLOBE NEWSWIRE) -- HiberGene Diagnostics, a company focussed on applying molecular technology to the infectious disease segment of the diagnostics market, has...